Highlights:

• Expanded participation in ATH434 Phase 2 clinical trial with sites opened for recruitment in Australia, the United States, and Italy
• Presented compelling bioMUSE data at two prestigious industry conferences
• Granted a 20-year patent for 100 new compounds targeting Parkinson's and Alzheimer's disease
• Cash balance on 31 December 2022 of A$25.3...